Business Wire

NY-UNIFRAX/CLEARLAKE

21.4.2021 13:02:11 CEST | Business Wire | Press release

Share
Unifrax Introduces FlexCat™, a New Custom High-Performance Specialty Catalyst Material

Unifrax , the leading manufacturer of high-performance specialty materials, today introduced FlexCat™ by Unifrax , a new high-surface area flexible media designed to provide enhanced catalyst effectiveness with increased yield using fewer raw materials. For use in fuel cells, specialty gas production, chemical processing, air purification and other applications, FlexCat offers catalyzers and industrial partners better performance, considerable cost savings, and improved safety for employees.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005357/en/

A game-changing solution for specialty catalyst markets

With many industries currently relying on alumina pellets to drive catalytic reactions, specialty chemical companies often grapple with stalled reactions because of clogged materials, large upfront investments and significant space requirements. They are also forced to contend with environmentally harmful emissions. To address these issues, Unifrax has designed a fibrous catalyst support solution that is 15 times lighter on average than the industry standard, while using significantly less precious metal catalysts and rare earth metals to drive an increase in yield while improving purity. This allows for increased output using existing equipment and enables a smaller reactor footprint for future designs. FlexCat can be incorporated into existing plant emission control systems to drive lower carbon footprints and allowing customers to meet tougher Environmental Protection Agency (EPA) standards.

“FlexCat is a truly revolutionary offering as a very lightweight, customized product form that is extremely durable in the harsh conditions typically encountered in many reactors,” said Chad Cannan, senior vice president of research and development, Unifrax. “FlexCat provides our industry partners with the potential to save millions of dollars across their operations in material costs, capital investments and improved quality from existing equipment. From cleaner emissions to meeting tougher EPA standards to increased purity, flow rates, and conversion speeds, the introduction of FlexCat is a true environmental, social, and governance (ESG) game changer for the industry.”

FlexCat is also poised to impact the hydrogen economy. As the demand for hydrogen increases, FlexCat supports the growth of hydrogen production through better selectivity and increased yield using significantly less catalyst material. FlexCat technology drives greater adoption by utilizing smaller and more efficient units that span from fuel cells to consumer devices.

Fiber-based technology that delivers

Leveraging the effective surface area of Unifrax’s unique fibrous material, FlexCat offers enhanced outputs by providing a more tortuous path for improved catalysis inside a reactor. FlexCat eliminates the need for any prewash or zeolite-coating process before applying catalyst metals. Testing to date has shown:

  • Ability to use up to 80 percent less metal, including platinum group metals (PGMs), while obtaining the same conversion yield
  • Extreme durability to nearly 1,850°F (~1,000°C) with more consistent product purity
  • Enhanced conversion and selectivity of catalytic reactions, even after aging, allowing industrial plants better output with existing equipment
  • Strong adhesion of PGMs and almost no loss of catalyst, even after thermal aging

FlexCat’s lightweight fiber mat structure allows for safer installation and removal, and limits hazardous waste, important benefits for Unifrax’s client’s workforce and the safety of the environment.

FlexCat and Unifrax’s deep technology portfolio

FlexCat is Unifrax’s first step into industrial catalysis, building on the company’s deep history of fiber-based technology and manufacturing. Unifrax has a track record of 75+ years developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, including electric vehicles, aerospace and chemical processing.

“Unifrax continues to pursue its mission to provide greener, cleaner, and safer solutions for our customers and partners. FlexCat is a revolutionary step forward for industrial catalysis that delivers on those three pillars,” commented John Dandolph, president and CEO, Unifrax. “Unifrax has worked closely with petrochemical and renewable fuels partners throughout our company’s history. As these industries look for new and innovative technologies to deliver cost-savings and efficiencies that current products can’t offer today, products like FlexCat, along with our new vehicle emissions technology Eco-lytic™ , deliver unique, game-changing solutions to catalysis industries overall. These products will have a transformational impact on safety, cost, and the environment in hundreds of industrial and chemical processes.”

Customizable for individual partners, processes and specific reactions, FlexCat can be manufactured at scale today. Unifrax will be available at Hydrogen 2021 Digital Conference & Exhibition to discuss in more with interested parties. For more information on the event visit this link .

Learn more about FlexCat at www.unifrax.com/landing-page/flexcat/ .

About Unifrax

Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn , and Facebook .

About Clearlake

Founded in 2006, Clearlake Capital Group, L.P. is an investment firm operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $35 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye